CTIS2023-509633-39-00进行中（未招募）1 期
A first-in-human, open-label, multicenter Phase I/II study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1) - ANV600-001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Anaveon AG
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial;, 10. Female participants who are not postmenopausal, and who have not undergone surgical sterilization, must agree to use highly effective methods of contraception during the treatment period and for 6 months after the last dose of study treatment. They must also agree not to donate eggs (ova, oocytes) during the same timeframe;, 11. Male participants with partners of childbearing potential must agree to use highly effective methods of contraception and barrier contraception (condom) during the treatment period and for 6 months after the last dose of study treatment. They must also agree not to donate sperm during the same timeframe., 2. Life-expectancy = 3 months;, 3. Must be able to comply with the Protocol as judged by the Investigator;, 4. Be = 18 years of age on day of signing informed consent;, 5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;, 6. Have measurable disease per RECIST v1.1 as assessed by the local site investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions;, 7. Phase I : Participants with advanced unresectable or metastatic solid tumors for which no standard of care treatments are available, or participants who cannot tolerate such treatment. Phase II: Additional cohort specific criteria apply;, 8. Have adequate organ function as defined in the protocol;, 9. Negative serum pregnancy test within 7 days prior to the first dose of study treatment in women of childbearing potential and women <12 months after menopause;
排除标准
- •1. For Phase I: Participants with pancreatic cancer (e.g. PDAC) or primary or secondary adrenal insufficiency;, 18. Have uncontrolled hepatitis B infection or hepatitis C infection;, 19. Have a history of an acute coronary event (e.g., myocardial infarction) within 3 months prior to study Day 1, uncontrolled and symptomatic coronary artery disease, or congestive heart failure NYHA Class III/IV;, 2. For Phase II: Participants with uveal and mucosal melanoma, and participants with primary tumor site of nasopharynx;, 20. Have an average QTcF interval >470 msec at screening;, 21. Have received a live vaccine, live-attenuated vaccine, mRNA-Based or Virus-Vectored vaccines within 30 days of study Day 1;, 22. Have a known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study;, 23. Have a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator;, 24. Are pregnant, breastfeeding or expecting to conceive or father children during the study, from the screening visit through 6 months after the last dose of study treatment., 3. History of allergic reactions attributed to any of the excipients of ANV600, such as sucrose, histidine or polysorbate 80. For combination only: Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients;, 4. Have received investigational agent (including investigational device) within 4 weeks or an interval of five half-lives of the respective investigational agent prior to study Day 1; whichever is shorter;, 10. Have a known additional malignancy that is progressing or has required active treatment within the past 3 years;, 5. Have received IL-2 or IL-2 analogues as anti-cancer therapy within 18 months prior to study Day 1 (except IL-2 given in combination with cell therapy [e.g. TILs]);, 6. Have not recovered (i.e., = Grade 1 at baseline) from AEs resulting from prior immunotherapies with the following exceptions: a. Autoimmune AEs controlled by replacement therapy (e.g., hypothyroidism, adrenal insufficiency) b. Vitiligo or alopecia c. Psoriasis;, 7. Have received prior systemic anti-cancer therapy including investigational agents within 4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs) prior to treatment;, 8. For combination only: Have received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher irAE;, 9. Have known active central nervous system metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment;, 25. Are deprived of liberty by judicial or administrative decision and/or subject to a legal protection measure (
研究者
相似试验
尚未招募
1 期
A Safety and Tolerability Study Evaluating CTX320 in Subjects With Elevated Lipoprotein(a) and a History of Atherosclerotic Cardiovascular Disease or Calcific Aortic Valve Stenosis.Cardiovascular - Other cardiovascular diseasesElevated Lipoprotein(a)Calcific Aortic Valve StenosisAtherosclerotic Cardiovascular DiseaseMetabolic and Endocrine - Other metabolic disordersACTRN12623001095651CRISPR Therapeutics AG24
招募中
1 期
A Safety and Tolerability Study Evaluating CTX310 in Subjects With Refractory DyslipidemiasACTRN12623000809639CRISPR Therapeutics AG24
招募中
1 期
Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancerSolid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065143Term: Malignant solid tumour Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10043302Term: Testicular cancer Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10007460Term: Carcinoma of unknown primary Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2024-512639-58-00BioNTech SE330
进行中（未招募）
1 期
Safety and preliminary efficacy trial of BNT142 in patients with CLDN6 positive solid tumorsClaudin 6 (CLDN6)-positive advanced solid tumorsMedDRA version: 21.0Level: LLTClassification code 10043302Term: Testicular cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10014733Term: Endometrial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10007460Term: Carcinoma of unknown primarySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005481-18-ESBioNTech SE216
尚未招募
2 期
First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumorstumors10027655cancerNL-OMON53910BioNTech SE14